Publications by authors named "Liselot B J Valkenburg-van Iersel"
Article Synopsis
- * Out of 24 patients, 46% showed clinical benefit, with a significant number achieving an objective response, and the overall treatment was considered safe with no unexpected side effects.
- * Whole genome sequencing helped identify potential resistance reasons in some patients, reinforcing the clinical significance of targeted therapy for HER2+mCRC.
Article Synopsis
- The study aimed to assess the effects of the COVID-19 pandemic on pancreatic cancer care by analyzing data from the Netherlands Cancer Registry for patients diagnosed between 2017 and 2020.
- The findings showed that while the incidence of pancreatic cancer was comparable in 2020 and previous years for the second quarter, there was an increase in cases with metastatic disease in the fourth quarter of 2020.
- Overall, the pandemic had a minor impact on patient care and outcomes, with the Dutch healthcare system maintaining essential services for these patients.
Background: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (DA). The aim of this study was to assess treatment modalities and overall survival by tumor origin.
Methods: Patients diagnosed with non-metastatic periampullary cancer in 2012-2018 were identified from the Netherlands Cancer Registry.
The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic ductal adenocarcinoma (PDAC) was shown by the ESPAC-4 trial. Real-world data on the effectiveness of gemcitabine plus capecitabine (GEMCAP), in patients ineligible for mFOLFIRINOX, are lacking. Our study assessed whether adjuvant GEMCAP is superior to GEM in a nationwide cohort.
View Article and Find Full Text PDFIntroduction: Ampullary cancer is rare and as a result epidemiological data are scarce. The aim of this population-based study was to determine the trends in incidence, treatment and overall survival (OS) in patients with ampullary adenocarcinoma in the Netherlands between 1989 and 2016.
Methods: Patients diagnosed with ampullary adenocarcinoma were identified from the Netherlands Cancer Registry.
Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci
July 2011
A bioanalytical assay for the new poly(ADP-ribose) polymerase-1 inhibitor olaparib in combination with melphalan was developed and validated. For the quantitative assay, human plasma samples were pre-treated on ice using protein precipitation with 2% (v/v) acetic acid in acetonitrile containing erlotinib and melphalan-d₈ as internal standards. The extract was diluted with water and injected into the chromatographic system.
View Article and Find Full Text PDF